Xconomy.com -- The liver is hot in the biotech world. Cambridge, MA-based Vertex Pharmaceuticals (NASDAQ: VRTX) has made headlines this year with an antiviral drug that it hopes will do for hepatitis C—a chronic liver-damaging condition affecting millions of people—what a previous generation of treatments did for HIV.
